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Background: Breast cancer is a heterogeneous disease comprising several biologically different types, exhibiting
diverse responses to treatment. In the past years, gene expression profiling has led to definition of several “intrinsic
subtypes” of breast cancer (basal-like, HER2-enriched, luminal-A, luminal-B and normal-like), and microarray based
predictors such as PAM50 have been developed. Despite their advantage over traditional histopathological
classification, precise identification of breast cancer subtypes, especially within the largest and highly variable
luminal-A class, remains a challenge. In this study, we revisited the molecular classification of breast tumors using
both expression and methylation data obtained from The Cancer Genome Atlas (TCGA).
Methods: Unsupervised clustering was applied on 1148 and 679 breast cancer samples using RNA-Seq and DNA
methylation data, respectively. Clusters were evaluated using clinical information and by comparison to PAM50
subtypes. Differentially expressed genes and differentially methylated CpGs were tested for enrichment using
various annotation sets. Survival analysis was conducted on the identified clusters using the log-rank test and Cox
proportional hazards model.
Results: The clusters in both expression and methylation datasets had only moderate agreement with PAM50 calls,
while our partitioning of the luminal samples had better five-year prognostic value than the luminal-A/luminal-B
assignment as called by PAM50. Our analysis partitioned the expression profiles of the luminal-A samples into two
biologically distinct subgroups exhibiting differential expression of immune-related genes, with one subgroup
carrying significantly higher risk for five-year recurrence. Analysis of the luminal-A samples using methylation data
identified a cluster of patients with poorer survival, characterized by distinct hyper-methylation of developmental
genes. Cox multivariate survival analysis confirmed the prognostic significance of the two partitions after
adjustment for commonly used factors such as age and pathological stage.
Conclusions: Modern genomic datasets reveal large heterogeneity among luminal breast tumors. Our analysis of
these data provides two prognostic gene sets that dissect and explain tumor variability within the luminal-A
subgroup, thus, contributing to the advancement of subtype-specific diagnosis and treatment.
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Breast cancer is a heterogeneous disease exhibiting high
tumor variability in terms of the underlying biological
mechanisms, response to treatment, and overall survival
rate [1]. Accurate identification of the unique biological
features characterizing each subtype is pivotal for im-
proving our understanding of the disease, identifying
subtype-specific biomarkers, targeted drug development,
and better prediction of response to treatment.
Originally, therapeutic decisions in breast cancer
were guided by clinicopathologic parameters like
tumor size, presence of lymph-node/remote metasta-
ses, and histological grade. In addition, the status of three
immunohistochemistry biomarkers - estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2/ERBB2) allowed the de-
velopment of targeted therapies and proved predictive of
treatment response [2].
With the emergence of global molecular profiling tech-
niques, large genomic datasets became available for subtype
discovery using unsupervised algorithms. By this method-
ology, breast samples are partitioned into subgroups using
clustering algorithms, such as hierarchical clustering [3] or
K-Means, and then subgroup significance is evaluated using
the clinical data associated with the samples.
Initially, microarray data were used to define four mo-
lecular breast cancer subtypes (basal-like, HER2-enriched,
luminal and normal-like) based on characteristic gene ex-
pression signatures in correlation with clinical data [4].
These molecular subtypes correlated reasonably well with
the immunohistochemical biomarker-based classification.
Thus, basal-like samples are mostly triple-negative (ER-/
PR-/Her2-), luminal samples are mostly ER+, and HER2-
enriched tumors are characterized by amplification and
high expression of the HER2/ERBB2 gene [5, 6].
Subsequent analysis conducted on a larger dataset sepa-
rated the luminal subtype into two distinct subgroups
named luminal-A and luminal-B. Luminal-B tumors have
higher expression of proliferation genes including Ki-67,
and confer worse prognosis [7–9]. Moreover, luminal-B
tumors respond better to chemotherapy, while patients
with luminal-A cancer gain most benefit from antiestro-
gen treatment [10].
As the partitioning of breast tumors into five molecu-
lar subtypes has gained acceptance and popularity, sev-
eral expression-based predictors have been developed. A
central predictor is PAM50, which maps a tumor sample
to one of the five subtypes based on the gene expression
pattern of 50 genes [11]. Though expected to be more
robust than traditional classification systems that rely
only on a few biomarkers, the separation between
luminal-A and luminal-B by the various predictors is not
consistent, suggesting that these molecular subtypes may
not represent distinct coherent sample groups [12].Other attempts to classify breast tumors were based
on other profiling technologies such as miRNA arrays
[13, 14], copy number variations [15] or a combination
of several different technologies [16, 17]. The various
studies have different levels of agreement with the
expression-based molecular subtypes, but taken together
they strongly indicate the existence of additional, subtler
subtypes than the PAM50 subtypes [18].
Epigenetic modifications such as DNA methylation ar-
rays, which measure the methylation status of thousands
of CpG sites across the genome [19], were also used for
breast cancer classification. DNA methylation changes
were shown to play a pivotal role in cancer initiation
and progression [20, 21]. Particularly, promoter hyper-
methylation was associated with silencing of tumor sup-
pressor genes [22]. Several studies associated breast can-
cer molecular subtypes with specific methylation
patterns [23], while others showed that methylation data
may reveal additional complexity not captured at the ex-
pression level, possibly identifying finer patient groups
of clinical importance [24].
The large breast cancer dataset developed and pro-
vided by The Cancer Genome Atlas project [25] includes
more than a thousand breast tumor samples character-
ized by various modern high-throughput genomic tech-
nologies. This dataset constitutes a significant leap
forward compared to the older microarray-based data.
mRNA abundance levels are measured in TCGA dataset
using the RNA-Seq technology. This technology has in-
creased sensitivity and a higher dynamic range compared
to microarrays [20, 21]. DNA-methylation arrays applied
on the same samples can help decipher biological tumor
variability by epigenetic modifications not manifested at
the gene expression level.
The aim of this study was to improve the classification
of breast tumors based on the extensive TCGA expres-
sion and methylation data that have recently become
available. We utilized these datasets to revisit the current
classification of breast tumors into biologically distinct
subgroups. Our improved and refined classification may




Our initial question was whether unsupervised clustering
of all TCGA breast samples using the RNA-Seq data
would reconstruct the partition defined by PAM50. As the
luminal samples had the highest variability in our global
clustering, we also asked how the luminal samples would
cluster into two groups based on the RNA-Seq data, how
the resulting sample groups would compare to the
PAM50 partition into luminal-A and luminal-B, and
whether that partition would have a clinical advantage
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into the internal structure of the highly variable luminal-A
samples, we asked whether this PAM50 group can be
further partitioned into finer subgroups with biological
distinctness and clinical significance. We then used en-
richment analysis to explore the biological mechanisms
underlying the new luminal-A subgroups.
We asked similar questions about breast tumor variability
at the epigenetic level. We evaluated the methylation-based
partition of all breast tumors, all the luminal samples and
the highly heterogeneous luminal-A, and compared
the resulting partitions to PAM50. To examine the
biological characteristics of differentially methylated
CpGs (DMCs) separating the new methylation-based
luminal-A subgroups, we conducted enrichment ana-
lysis. Finally, we performed multivariate COX survival
analysis to determine whether the new subgroups
have independent prognostic value.
Data acquisition and preprocessing
TCGA data on invasive carcinoma of the breast were down-
loaded from the UCSC Cancer Browser web site [26] together
with accompanying clinical information. The downloaded
RNA-Seq gene expression dataset (Illumina HiSeq platform,
gene level RSEM-normalized [27], log2 transformed) included
1215 samples of which 11 samples from male patients, 8
metastatic samples, and 30 samples of unknown tissue
source were filtered out. PAM50 calls (obtained directly
from UNC, including PAM50 proliferation scores) were
available for 1148 of the filtered samples, and were distrib-
uted as follows: 183 basal-like, 78 HER2-enriched, 534
luminal-A, 203 luminal-B and 150 normal-like.
We also downloaded DNA methylation profiles (Illumina
Infinium Human Methylation 450K platform, beta values)
[19] containing 872 samples of which 8 male samples, 5
metastatic samples and 19 samples of unknown tissue
source were filtered out. We used only 679 tumor samples
for which PAM50 calls were available, including 124 basal-
like, 42 HER2-enriched, 378 luminal-A and 135 luminal-B
samples. Our analysis used only the 107,639 probes of the
Infinium-I design type for which a gene symbol was avail-
able. This allowed us to bypass the bias of the two probe
designs included on the array, to focus on differentially
methylated sites that are associated with known genes, and
also to reduce the number of analyzed features.
Unsupervised analysis of the tumor samples
Unsupervised analysis of the various sample subsets was
executed by clustering the samples based on the 2000
features (genes or CpGs) showing the highest variability
over the samples included in each analysis. We used the
K-Means clustering algorithm in Matlab (release 2015a)
with correlation distance and 100 replicates from which
a solution minimizing the sum of point-to-centroiddistances was chosen. Due to the high variability among
sample subgroups in the breast cancer datasets, reselect-
ing the top variable genes for the analysis of each sample
set (and renormalizing accordingly) is crucial to ensure
use of the features most relevant to that set. Each feature
was independently centered and normalized over the an-
alyzed samples prior to clustering.
Cohort descriptions for the samples used in each ana-
lysis are provided in Additional file 1 (Tables S-1A, S-2A,
S-3A for the RNA-Seq analyses and Tables S-6A, S-7A
and S-8A for the DNA methylation analysis). The
TCGA sample Ids included in each analysis are listed
in Additional file 2.
Sample cluster enrichment and survival analysis
To evaluate the clinical relevance of the sample clusters
obtained in each unsupervised analysis, we used the ex-
tensive clinical information available from TCGA for each
sample. Enrichment significance of sample clusters for
categorical variables (such as the PAM50 subtype or histo-
logical type) was calculated using the false discovery rate
(FDR)-corrected hypergeometric test. For numeric vari-
ables (such as age, percent tumor nuclei, and others) the
difference between sample groups was evaluated using the
Wilcoxon rank–sum test (Mann–Whitney U test).
Survival and recurrence-free survival curves were plot-
ted using the Kaplan-Meier estimator [28] and p values
for the difference in survival for each group versus all
other groups were calculated using the log-rank (Mantel–
Haenszel) test [29, 30]. Cox univariate and multivariate
survival analyses were conducted using Matlab implemen-
tation; p values were corrected using FDR. The analysis
and visualization scripts are publicly available as an inter-
active graphical tool named PROMO [31].
Analysis of differentially expressed genes and gene
enrichment
A list of genes that have the highest differential expres-
sion between the two RNA-Seq-based sample groups
LumA-R1 and LumA-R2 was generated by applying the
Wilcoxon rank–sum test on all dataset genes exhibiting
non-zero variance (n = 19,913) after flooring all dataset
values to 1 and ceiling to 14. We selected the 1000 genes
exhibiting the most significant p values that also have a
median difference of at least 0.5 (log2-transformed
RSEM expression values). All genes on the list had sig-
nificantly higher expression in the LumA-R2 sample
group (the lowest p value was 8.1e-28).
Gene enrichment tests were performed on these 1000
genes against a background of all genes included in the
rank–sum test. The Expander software suite [32, 33]
was used to detect significant enrichments for Gene
Ontology (GO) [34], Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways [35], Wiki-Pathways
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were also performed using the GOrilla tool [37]. The
list of 1000 top differentially expressed genes and de-
tailed results of the enrichment analysis are provided
in Additional file 3.
Analysis of differentially methylated CpGs, correlation to
expression and CpG enrichment
To identify CpGs that are differentially methylated be-
tween LumA-M1 and LumA-M3 samples we applied the
rank–sum test on all CpGs that survived our preprocess-
ing and also had non-zero variability in the relevant
samples (n = 93,880). We then selected the 1000 CpGs
that had the highest significance and a minimal median
difference of 0.2 (in Beta values). All selected CpGs had
significantly higher mean methylation in the LumA-M1
compared to the LumA-M3 group.
To focus on DMCs with genes that had concomitant
changes in expression, we calculated Spearman correlation
between each CpG and the expression profile of its associ-
ated gene based on the Illumina probe-set annotation.
The correlation values enabled the identification of 586
DMCs (rank–sum p value <0.01, median difference >0.2)
negatively correlated to expression (R < -0.2) and a second
smaller group of 212 DMCs positively correlated (R > 0.2)
with expression.
We used the array CpG annotations provided by Illumina
to calculate enrichment of each one of the three CpG lists
(top 1000 DMCs, 586 negatively correlated DMCs and 212
positively correlated DMCs) for features like differentially
methylated regions (DMRs), enhancer regions, UCSC
RefGene groups and regulatory feature groups. Gene en-
richment analysis was performed on the unique genes com-
posing each CpG list, using the Expander and Gorilla tools
as described above. Enrichment for InterPro [38] terms
was calculated using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) [39].
Enrichment for tumor suppressor genes was calculated
by hypergeometric test based on the TSGene [40] cata-
log. The lists of differentially methylated CpGs in
addition to detailed results of the enrichment analysis
are provided in Additional files 4, 5 and 6.
Results
Separation of luminal-A and luminal-B samples is not
reconstructed by RNA-Seq unsupervised analysis
We started by evaluating the global sample structure
within the RNA-Seq gene expression data obtained from
TCGA. We applied unsupervised analysis on both tumor
(n = 1035) and normal (n = 113) breast samples using the
K-Means clustering algorithm over the top 2000 variable
genes. As our initial goal was to compare the resulting
partition into the four intrinsic molecular types, we used
K = 5 (corresponding to the four types represented byPAM50 label classes in addition to normal). The results
are shown in Fig. 1.
The resulting clusters exhibited moderate correspond-
ence with PAM50 labels: most basal-like, normal and
HER2-enriched samples fell into three different clusters
(numbers 4, 5, and 3, respectively, listed in decreasing
levels of homogeneity), whereas the luminal samples ex-
hibited much greater variability. Importantly, most
luminal-A sample were split between two different clus-
ters - a homogenous luminal-A cluster (cluster 2), and a
cluster composed of a mix of luminal-A and luminal-B
samples (cluster 1).
Furthermore, the samples assigned to cluster 2 exhib-
ited a very distinct expression pattern, overexpressing
1184 genes compared to cluster 1 (out of the 1421
differentially expressed genes, see “Methods”). Cluster 1
samples overexpressed only 229 genes compared to clus-
ter 2 (see Additional file 1: Figure S-1E for per-cluster
distribution and Additional file 1: Figure S-1F for results
of differential gene expression analysis).
According to these results, the variability within the lu-
minal samples is not sufficiently captured by the PAM50
luminal-A and luminal-B subtypes. Specifically, they sug-
gest that luminal-A samples can be further partitioned
into finer subgroups, possibly having clinical meaning.
Unsupervised partition of luminal samples predicts
survival and recurrence better than PAM50
To further investigate the variability among luminal
samples, we clustered the 737 luminal samples (534
luminal-A and 203 luminal-B samples based on PAM50
labels) into two groups. The results are shown in Fig. 2a.
Similar to the global analysis, the luminal-A samples
were divided between a luminal-A mostly homogenous
cluster (cluster 2) and a cluster composed of both
luminal-A and luminal-B samples (cluster 1).
Survival analysis performed on the two luminal parti-
tions (the PAM50 luminal-A/luminal-B partition, and
the two K-Means clusters shown in Fig. 2a) showed that
the RNA-Seq-based clustering partition outperforms the
luminal-A/luminal-B distinction in terms of both survival
and recurrence (5-year survival plots are shown in Fig. 2b;
also see Additional file 1: Figure S-2A for overall survival
plots). Hence, the signal identified by our unsupervised
analysis of the RNA-Seq data translates into a clinically
relevant partition of the luminal samples that has better
predictive power than the PAM50 luminal-A/luminal-B
partition in terms of both survival and recurrence.
Luminal-A samples have two distinct classes exhibiting
clinical significance
As the luminal-A samples displayed the highest level of
variability by consistently falling into two major sub-
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Fig. 1 Global unsupervised clustering of 1148 breast samples using RNA-Seq data. Applying the K-Means algorithm using K = 5 on the RNA-Seq
dataset yielded a partition exhibiting moderate agreement with PAM50 labels and the three immunohistochemical markers. Notably, luminal-A
samples were split between a rather homogenous cluster 2 and cluster 1, which is composed of a mix of luminal-A and luminal-B. a K-Means
clusters. b PAM50 calls. c Estrogen receptor (ER) status. d Progesterone receptor (PR) status. e Human epidermal growth factor receptor 2
(HER2) status
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tures. To this end, we re-clustered only the 534 luminal-
A samples into two groups (Fig. 3a). As the resulting
clusters were found to be significantly enriched for vari-
ous clinical variables, we designated them as LumA-R1
(n = 258) and LumA-R2 (n = 276).
The most apparent property of the resulting partition
was the general overexpression pattern in LumA-R2 sam-
ples compared to LumA-R1 samples. Indeed, out of the
2000 genes selected for clustering, 1276 were differentially
expressed and 1068 of them were overexpressed in
LumA-R2 samples (based on the FDR-corrected rank-sum
test). A very similar partition (chi-square, p = 1.1e-40) with
a parallel overexpression pattern was identified on a
microarray gene expression dataset also available from
TCGA for a subset of the luminal-A samples used here
(n = 265). This supports the conclusion that the partition
and distinct overexpression pattern we observed are not
an artifact originating from RNA-Seq measurementtechnology or from any normalization protocols applied
on the dataset (see Additional file 1, section 4).
Recurrence analysis performed on these two luminal-
A subgroups identified that LumA-R2 samples were as-
sociated with a significantly reduced 5-year recurrence
rate (p = 0.0076, Fig. 3b). Enrichment analyses on add-
itional clinical information available for the samples
revealed that LumA-R1 and LumA-R2 subgroups are
enriched with ductal (p = 2.1e-05) and lobular (p = 9.7e-
12) histological types, respectively. LumA-R1 samples
were associated with a higher proliferation score (p = 8.9e-
25), older age (p = 2.6e-05), and a slight but significant de-
crease in normal cell percent (p = 2.8e-08) accompanied
by an increase in tumor nuclei percent (p = 2.6e-12) com-
pared with LumA-R2 samples (see Table 1).
Comparing the luminal-A partition shown in Fig. 3a to
the groups formed when clustering all the luminal sam-
ples (Fig. 2a), we note that almost all LumA-R2 samples
are contained within cluster 2 (composed of mainly
ab
Fig. 2 Unsupervised analysis of luminal breast samples using RNA-Seq data. a Applying the K-Means algorithm on the 737 luminal samples using
K = 2 splits the samples into two subgroups exhibiting better five-year prognostic value than the PAM50 luminal-A/luminal-B partition. b Five-year
survival and recurrence for the two luminal breast cancer partitions. The partition into two RNA-Seq-based clusters outperforms PAM50 partition of the
luminal samples in both survival and recurrence. P values were calculated using the log-rank test
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tained within cluster 1 (composed of a mix of luminal-A
and luminal-B samples) (see the second label bar inFig. 3a). This suggests that LumA-R1 samples are more
similar in their expression profile to luminal-B samples
compared with LumA-R2 samples.
ab
Fig. 3 Unsupervised analysis of luminal-A (LumA) breast samples. a Clustering of 534 RNA-Seq profiles partitions the data into two groups exhibiting
distinct expression profiles. The clusters also show significant enrichment for clinical variables including recurrence, proliferation score, age, and
histology. The bars below the heatmap show, from top to bottom, the partition of the samples, the designation of the samples according to the
clustering of all luminal samples (see Fig. 2), histological type, and proliferation scores. b Five-year survival and recurrence analysis in the two luminal-A
subgroups. LumA-R2 samples exhibit significantly reduced five-year recurrence rate compared with LumA-R1
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expression profiles
In order to identify genes that distinguish best between
LumA-R1 and LumA-R2 samples, we created a list of the
1000 most differentially expressed genes (see “Methods”).
In agreement with the general expression pattern de-
scribed earlier, all genes in the list were overexpressed in
LumA-R2 compared to LumA-R1 samples. The most sig-
nificant categories in the enrichment analysis performed
in this list were related to the immune system regulation.
The more specific category of T cell receptor signaling
genes appeared consistently in analyses based on various
annotation databases (Gene Ontology: "T Cell activation"
p = 1e-05, KEGG Pathway: "T Cell receptor signaling path-
way" p = 3e-07, Wiki-Pathway: "T Cell receptor (TCR)Signaling Pathway" p = 1.09e-07). Other enrichments of
interest included the KEGG Pathways "Cytokine-cytokine
receptor interaction" (p = 2.13e-13), "Chemokine signaling
pathway" (p = 1.14e-09) and Wiki-Pathway "B Cell Recep-
tor Signaling Pathway" (p = 1.72e-06). See Table 2 for a list
of the most significant categories, and Additional file 1,
section 5 for the full list.
Careful examination of the gene list revealed that
LumA-R2 samples overexpress genes that are typically
expressed by various immune system cells (e.g., the
leukocyte marker CD45/PTPRC, T cell marker CD3, and
B cell marker CD19) [41–44]. A significant number of
overexpressed genes are related to the T cell receptor
(CD3D, CD3E, CD3G, and CD247) and the upstream
part of its signaling pathway (ZAP70, LCK, FYN, LAT,
Table 2 The most enriched functional categories among the
1000 genes most differentially expressed between LumA-R1 and
LumA-R2 samples
Enrichment type Term Number
of genes
P value
Gene Ontology Regulation of immune
system process
152 3.74e-50







Cell activation 91 4.59e-28






Leukocyte activation 67 1.95e-26
Positive regulation of cell
activation
56 5.13e-24
T cell activation 45 4.93e-22
Regulation of cell proliferation 128 1.83e-21
KEGG Pathways Cytokine-cytokine receptor
interaction
56 4.76e-22




Primary immunodeficiency 16 8.70e-13




T cell receptor signaling
pathway
20 1.30e-07
Allograft rejection 11 6.44e-07
Natural killer cell mediated
cytotoxicity
20 5.66e-06
Pathways in cancer 34 1.49e-05
Wiki-Pathways TCR signaling pathway 10 1.55e-09
B cell receptor signaling
pathway
10 1.72e-06








All the genes on the list showed significantly higher expression on the LumA-
R2 samples compared to LumA-R1 samples
Table 1 The main characteristics distinguishing between the
luminal-A subgroups, LumA-R1 and LumA-R2










Age, years, average 61.5 57.4 2.6e-05
Proliferation score -0.4 -0.6 8.9e-25
Tumor nuclei percent 80 % 73 % 2.6e-12
Normal cell percent 2.9 % 6.1 % 2.8e-08
Gene overexpression 194 1068
Average values are shown for each group where relevant. Gene overexpression is
computed with respect to the 2000 genes used for clustering.
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pressed genes were related to T cell or natural killer
(NK)-mediated cytotoxic activities (GZMA, GZMB,
GZMH, GZMM, and PRF1) [46, 47].
We also observed that the overexpression of immune
receptor genes in LumA-R2 samples was accompanied
by overexpression of several chemokine genes (CCL5,
CCL17, CCL19, and CCL21) and their corresponding re-
ceptors (CCR5, CCR4, and CCR7). Topping the list of
overexpressed genes in Lum-A-R2 samples (ranked by p
value) is the Interleukin-33 (IL-33) gene, which drives T
helper 2 (Th2) responses [48]. In summary, LumA-R2
samples exhibit better prognosis based on several clinical
parameters while overexpressing a significant number of
genes related to the immune system.
Analysis of DNA methylation identifies a luminal
subgroup characterized by hyper-methylation and a
significantly poorer outcome
The luminal-A tumors proved to be the most heteroge-
neous in our gene expression analysis. To further iden-
tify and characterize clinically meaningful subgroups
within the luminal-A group, we explored breast tumor
variability on the epigenetic level as well.
Using the Methylation 450K array dataset available from
TCGA, we started our analysis as in the expression data,
by clustering all 679 tumor samples into four groups, cor-
responding to the number of PAM50 classes. The result-
ing clusters (Fig. 5a) had modest agreement with the
expression-based PAM50 classes; all basal-like samples
were assigned to a single cluster exhibiting a distinct
hypo-methylation pattern (cluster 4), whereas HER2-
enriched samples were scattered over three different clus-
ters, indicating that this subtype has reduced manifest-
ation at the methylation level. Notably, most luminal
samples were assigned to three different clusters (1–3)
with methylation-level gradation on the top 2000 variable
CpGs. Cluster 1 exhibited a strong hyper-methylation pat-
tern, contained the highest ratio of luminal-B samples,and was associated with significantly poorer survival com-
pared to the three other clusters (p = 0.0001). Cluster 3,
on the other hand, exhibited opposite characteristics:
lower methylation levels, the lowest ratio of luminal-B
samples and a better outcome (p = 0.0129).
Fig. 4 LumA-R2 samples overexpress genes in the T cell receptor signaling pathway. The list of top 1000 genes differentially expressed in LumA-
R1 and LumA-R2 samples was found to be significantly enriched for the pathway genes (p= 1.3e-07). Genes marked in red are overexpressed in LumA-R2
samples. Pathway and graphics were taken from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database
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the 513 luminal A and B samples (Fig. 5b). Here we used
the top 2000 variable genes within these samples, to re-
move the effect of the other two subtypes on the cluster-
ing. Importantly, out of the 127 samples comprising the
hyper-methylated cluster 1, which was associated with
reduced survival (p = 2.6e-05), 76 samples were labeled
as luminal-A, a subtype usually associated with good
survival. In other words, approximately 20 % of the 378
luminal-A samples (as called by the expression-based
PAM50) included in the analysis, could actually be
assigned to a higher risk group based on methylation
data (see Additional file 1, section 7 for more details).
The three-way partition by methylation levels and its
association to differential survival risk also appeared
when we repeated the analysis in the group of 378luminal-A samples, using the top 2000 variable CpGs on
these samples (Fig. 5c). The three methylation-based
luminal-A clusters were designated LumA-M1, LumA-
M2 and LumA-M3. The 84-sample LumA-M1 cluster
(comprising approximately 22 % of the luminal-A sam-
ples) was associated with significantly reduced 5-year
survival (p = 0.0031).
Furthermore, the methylation-based partitioning of
the luminal-A samples (LumA-M1/2/3) correlated sig-
nificantly with the expression-based partitioning (LumA-
R1/2, chi-square p = 4.4e-08). The LumA-M2 cluster was
enriched for LumA-R1 samples (p = 1.4e-06) and the
LumA-M3 cluster was enriched for LumA-R2 samples
(p = 1.6e-08), showing that the expression and the
methylation-based patterns are related (see lower bar on






Luminal-A Breast Cancer Meth450 Dataset [2000 CpGs x 378 samples]


















Fig. 5 Unsupervised analysis of breast cancer tumors using DNA methylation data. Samples were clustered by K-Means based on correlation using
the top 2000 variable CpGs over each sample subset. a All 679 tumors. b The 579 samples identified as luminal-A and luminal-B by PAM50 classification.
c The 378 luminal A samples only. First bar below each expression matrix shows the assignment of the samples to methylation-based clusters. Second
bar (a and b) shows PAM50 calls for the samples. Second bar (c) presents the RNA-Seq based LumA-R1/2 subgroups defined in Figure 3. Right panels
show five-year Kaplan-Meier survival plots for the resulting groups
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guished by a robust hyper-methylation pattern.
Analysis of differentially methylated CpGs between the
LumA-M1 and LumA-M3 subgroups and their correlation
to gene expression
To uncover the biological features characterizing the dis-
tinct methylation patterns observed in the luminal-A
subgroups, we examined the 1000 top DMCs (see
“Methods”) between the hyper-methylated LumA-M1 (n
= 84) and the hypo-methylated LumA-M3 (n = 171).
These two sample subgroups represent the two extremes
of the methylation gradient observed in the luminal-A
samples. Of note, all 1000 top DMCs (representing 483
genes) were hyper-methylated in the LumA-M1 samples
compared to LumA-M3 samples.
Gene enrichment analysis associated these 483 genes
hyper-methylated on LumA-M1 samples with GO termsrelated to development, signaling, cell differentiation and
transcription regulation (p < 1e-15). The genes were also
enriched for the homeobox InterPro term (p = 3.6e-35),
in line with previous reports describing the methylation of
homeobox genes during breast tumorigenesis [49–51].
Further, the 483 genes were enriched for tumor suppres-
sor genes according to the TSGene catalog [40] (p = 1.5e-
03), including 48 such genes (see column 1 in Table 3).
Analysis for CpG features of the top 1000 DMCs re-
vealed significant enrichment for enhancer elements,
tissue-specific promoters and cancer-specific DMRs
(see column 1 in Table 4).
The databases Gene Ontology, InterPro and Tumor
Suppressor Genes 2.0 were used to test the hyper-
methylated genes for enrichment. Group 1 is composed
of the 1000 top differentially methylated CpGs with a
mean difference of at least 0.2. All the CpGs on this list
had significant hyper-methylation in the LumA-M1
Table 3 Gene enrichment in the three subsets of CpGs exhibiting differential methylation between the LumA-M1 and LumA-M3
subgroups
(1) (2) (3)
Hyper-methylated CpGs Negative: R < -0.2 Positive: R > 0.2
1000 CpGs, 483 genes 586 CpGs, 340 genes 212 CpGs, 125 genes
Term P value Term P value Term P value
Gene Ontology Anatomical structure
development
6.1e-28 Developmental process 7.8e-06 Pattern specification
process
1.1e-13
Developmental process 2.0e-25 Single organism signaling 2.4e-05 Regionalization 1.1e-12
Multicellular organismal
process















Signaling 1.9e-21 Anatomical structure
development
8.0e-05 Developmental process 1.7e-11
Cell-cell signaling 1.7e-21 Cell-cell signaling 1.8e-04 Embryonic
morphogenesis
1.1e-10





1.4e-19 Synaptic transmission 4.4e-04 Organ development 5.3e-10
Regulation of transcription







InterPro Homeobox 3.6e-35 Homeobox 1.1e-04 Homeobox 2.1e-31
Tumor suppressor
genes (TSGene 2.0)
AHRR, AKR1B1, BMP2, C2orf40,
CDH4, CDO1, CDX2, CNTNAP2,
CSMD1, DLK1, DSC3, EBF3,
EDNRB, FAT4, FOXA2, FOXC1,
GALR1, GREM1, GRIN2A, ID4,
IRF4, IRX1, LHX4, MAL, MIR124-2,
MIR124-3, MIR125B1, MIR129-2,
MIR137, MIR9-3, ONECUT1,
OPCML, PAX5, PAX6, PCDH8,
PHOX2A, PRKCB, PROX1,
PTGDR, RASL10B, SFRP1,
SFRP2, SHISA3, SLIT2, SOX7,
TBX5, UNC5D, ZIC1
1.5e-03 AKR1B1, ASCL1, BIN1, BMP4,
CCDC67, CDK6, CDO1, EBF3,
GSTP1, ID4, IRX1, L3MBTL4,




UBE2QL1, UNC5B, VIM, WT1






(48 genes) (29 genes) (14 genes)
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composed of the 586 CpGs with a differential methyla-
tion p value <0.01, a methylation mean difference >0.2
and Spearman-based correlation with expression <0.2.
Group 3 is composed of 212 CpGs with a differential
methylation p value <0.01, a methylation mean difference
>0.2 and Spearman-based correlation with expression >0.2.
As DNA-methylation is known to regulate gene ex-
pression and as hyper-methylation of promoters is asso-
ciated with gene silencing in cancer [52], we focused on
LumA-M1 hyper-methylated CpGs that affect the ex-
pression of their corresponding genes. To this end, we
used the RNA-Seq-based expression data available from
TCGA for the same 378 analyzed samples to generate a
second list of CpGs that are both hyper-methylated in
LumA-M1 samples (differential methylation p < 0.01,median difference of 0.2) and that have methylation
levels inversely correlated to the expression level of their
corresponding gene (Spearman correlation R < -0.2). As
can be seen in Table 4, the 586 CpGs that passed this filter
(corresponding to 340 genes) had significant over-
representation of upstream parts of their corresponding
genes (UCSC RefGene Group: TSS and 1st exon p < =4.4e-
05) and under-representation of gene body (p = 1.43e-16)
and 3'UTR (p = 5.83e-04). In terms of the regulatory feature
group, these 586 CpGs had over-representation of "Pro-
moter Associated Cell type specific" elements (p = 1.40e-04)
accompanied by highly significant under-representation of
"Promoter Associated" elements (p = 2.94e-31), suggesting
that the observed hyper-methylation pattern involves
tissue-specific promoters. Among the 340 under-expressed
genes containing the 586 hyper-methylated CpGs, there










CpG enrichment tests show that hyper-methylated CpGs negatively correlated with gene expression are enriched for upstream gene parts, whereas positively
correlated CpGs are enriched for the gene body. All three hyper-methylated CpG groups are enriched for informatically determined enhancer elements and
experimentally determined differentially methylated regions and DNAse hypersensitive sites. The p values represent hyper-geometric-based over-representation
or under-representation and are FDR corrected (significant p values are marked in bold). UTR untranslated region, DMR differentially methylated region
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that has previously been observed in breast cancer, such as
L3MBTL4 [53], ID4 [54], RUNX3 [55, 56], PROX1 [57],
SFRP1 [58] and others. Gene-level and CpG-level enrich-
ment for the negative correlations are shown in column 2
of Tables 3 and 4, respectively.
Interestingly, the 212 LumA-M1 hyper-methylated CpGs
that were positively correlated with expression (Spearman
R > 0.2) had higher enrichment of development-related
GO terms compared with negatively correlated CpGs
("pattern specification process" p = 1.07e-13, "embryonic
morphogenesis" p = 1.05e-10, "cell fate commitment"
p = 5.49e-10). In contrast to the negatively correlated
CpGs, they had high over-representation of "gene body"
and under-representation of "TSS" regions (UCSC RefGene
Group, p = 9.48e-20 and p = 7.28e-14, respectively). For
gene and CpG level enrichment for the positive correlations
see column 3 in Tables 3 and 4, respectively.The differential methylation pattern distinguishing
LumA-M1 from LumA-M3 samples could therefore be
characterized by hundreds of CpGs that are hyper-
methylated in the LumA-M1 samples. Distinct subsets
of these CpGs correlate negatively and positively with
the expression of developmental genes.
Cox survival analysis
In previous sections, we presented two different parti-
tions of luminal-A tumors based on genomic profiles,
with prognostic value: The LumA-R2 group (character-
ized by high expression of immune-related genes) was
associated with a reduced chance of 5-year recurrence,
whereas the LumA-M1 group (characterized by hyper-
methylation of CpGs located in developmental genes)
was associated with poorer survival. To determine the
prognostic contribution of the two partitions while
adjusting for other relevant explanatory variables, we
Table 5 Multivariate Cox analysis of luminal-A subgroups for five-year survival and five-year recurrence
Survival Recurrence
Variable Hazard ratio P value Hazard ratio P value
LumA-R (1 vs 2) 0.56 0.36991 0.06 0.00693
LumA-M (2, 3 vs 1) 6.68 0.00484 3.04 0.07028
Age (<60 vs > =60 years) 11.20 0.0037 1.03 0.96530
Pathologic stage (I, II vs. III, IV) 2.12 0.25519 1.93 0.26992
ER status 7.17 0.18095 0.00 0.99575
PR status 0.47 0.50039 0.29 0.29092
Her2 status 1.48 0.72659 0.64 0.68789
Significant p values are marked in boldface. ER estrogen receptor, PR progesterone receptor, Her2 human epidermal growth factor receptor 2
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LumA-R and LumA-M partitions (see Table 5). Patients
belonging to the LumA-M1 group had a 6.68-fold higher
estimated 5-year death hazard compared with the other
groups in the Cox multivariate model after adjustment for
age, pathological stage, ER status, PR status and Her2 sta-
tus. Patients belonging to the LumA-R2 group had a de-
creased recurrence hazard of 0.06 (that is, 94 % decrease)
compared with LumA-R1 patients, after similar adjust-
ment. The results reaffirm the independent prognostic
value of the LumA-R2 and the LumA-M1 classes (see
Additional file 1, section 10 for univariate analysis).
Discussion
Gene expression profiling has become a useful tool for
breast cancer classification and for direction of treatment
[59]. Although the HER2-enriched and the basal-like sub-
groups are well-defined and indicative for anti-Her2 and
chemotherapy treatment, respectively, the ER-positive lu-
minal subgroup still presents a clinical challenge. In gen-
eral, all luminal tumors are candidates for anti-hormonal
therapy. However, some tumors within this class, often
with a more proliferative potential and conferring poorer
outcome, are considered for additional therapy. Accord-
ingly, the common classification based on the molecular
intrinsic subtypes divides the luminal tumors into the
luminal-A tumors, which have a better outcome, and the
more proliferative luminal-B tumor subgroups, which
have a worse outcome. However, this classification is sub-
optimal for clinical decisions because the luminal tumors
present a phenotypic and prognostic range rather than an
exact partition to either group.
In this study, we applied unsupervised analysis on breast
tumor samples using both expression and methylation
profiles to reveal new genetic and epigenetic patterns that
correlate with a clinical outcome, and compared them to
the PAM50 subtypes. Overall, our analyses showed that
the separation between luminal-A and luminal-B (as rep-
resented by PAM50 labels) is not clear-cut, but rather rep-
resents a phenotypic continuum (as previously observed
[12, 60, 61]). In fact, each of the gene expression andmethylation datasets used in our analysis separately en-
abled partitioning of the luminal samples into groups with
better prognostic value than that of PAM50.
Furthermore, when we focused on the PAM50-
designated luminal-A samples only, the RNA-Seq expres-
sion profiles split the luminal-A samples into two
subgroups (Fig. 3a). The lobular-enriched LumA-R2
sample group, characterized by a distinct gene over-
expression pattern, was associated with significantly
reduced recurrence risk compared with the more prolifer-
ative LumA-R1 subgroup. Interestingly, genes constituting
that over-expression pattern were significantly enriched
for functions related to the immune system, including the
more specific enrichment of chemokines and genes of up-
stream T cell receptor signaling pathways. We postulate
that the significantly elevated mRNA levels of immune re-
lated genes in LumA-R2 samples are indicative of increased
infiltration levels of immune system cells into these tumors.
Typically, chemokines serve as ligands that by binding
to their corresponding receptors, attract immune system
cells to the site where they are secreted [62, 63]. LumA-R2
samples over-expressed several chemokines and their cor-
responding receptors. The simultaneous over-expression
of both the chemokine CCL5 (previously found to be
highly expressed by breast cancer cells [64]) and one of its
receptors - CCR5 (expressed among others by CD8+ cyto-
toxic T cells), suggests that tumor cell-derived CCL5 at-
tracts CD8+ cytotoxic T lymphocytes (CTLs) to LumA-R2
tumors. Similarly, the over-expressed chemokines CCL19
and CCL21 may be expressed by the tumor cells, whereas
their CCR7 receptor may be expressed by licensed DC or
(less typically) by naive and central memory T cells.
In line with this possibility, the over-expressed genes
in LumA-R2 samples included genes typical of CTLs
(and also natural killer (NK) cells), which may lead to
anti-tumor cytotoxic activities exerted by the granzyme
(GZMA and GZMB) and perforin pathways (PRF1). Ac-
cordingly, over-expression of T cell activation genes was
also detected in patients with LumA-R2 tumors. Not-
ably, the over-expressed genes are concentrated at the
upstream part of the T cell receptor-signaling pathway
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fectors are not enriched in LumA-R2 samples; however,
it is of interest to see that the alpha chain of IL-15R was
over-expressed in these samples, suggesting that T cell
activation processes may indeed come into effect in this
subgroup of patients.
How could the over-expression of the immune genes
by LumA-R2 samples be related, if at all, to reduced
tumor recurrence? It is possible that only LumA-R2 tu-
mors can release chemoattractants that induce the mi-
gration of antigen-specific, possibly beneficial, leukocyte
subpopulations to the tumor site. Despite recent reports
associating tumor infiltrating lymphocytes with a better
prognosis [65–67], it is yet to be determined how en-
hanced immunogenic activity in the LumA-R2 tumors
may improve their outcome. Possibly in the future, this
LumA-R2 characteristic pattern may direct emerging
immune-checkpoint-related therapies [68].
The role of epigenetic regulation in malignant pro-
cesses is increasingly recognized. Indeed, our analysis of
DNA methylation data partitioned the breast tumor
samples into four clusters showing only moderate agree-
ment with the expression-based PAM50 subtypes. In line
with previous studies [24, 69], one cluster had a hypo-
methylation pattern and corresponded with the PAM50
basal-like subgroup that was associated with poorer out-
come. However, the luminal samples did not cluster
neatly into the PAM50 luminal-A and luminal-B sub-
groups. Instead, three luminal clusters with increasing
methylation levels were obtained (clusters 1–3 in Fig. 5a),
of which the most hyper-methylated cluster was associ-
ated with significantly poorer 5-year prognosis. In fact,
even when we clustered only the luminal-A samples
(Fig. 5c), the hyper-methylated cluster 1 (LumA-M1)
was still associated with significantly poorer survival
compared to the other two clusters (LumA-M2 and
LumA-M3).
Notably, the top 1000 differentially methylated CpG loci,
all hyper-methylated on LumA-M1 samples, had enrich-
ment for genes involved in morphogenesis, differentiation,
and developmental processes. Moreover, the CpG hyper-
methylation correlated with under-expression of develop-
mental genes, including various tumor suppressor genes.
Indeed, hyper-methylation of developmental genes in
luminal breast tumors was previously reported [70, 71],
secondary to repressive histone marks, which direct de
novo methylation. Moreover, hyper-methylation was
implicated in normal processes of cell aging and in
tumorigenesis [61]. Taken together, the methylation-based
analysis suggests a poorer outcome for luminal tumors
with a characteristic hyper-methylation pattern, whether
in the luminal-A or in the luminal-B subgroups. The
hyper-methylation-associated silencing of developmental
and tumor suppressor genes may indeed explain thesefindings. More importantly, within the luminal-A sub-
group that is generally associated with a better outcome,
the hyper-methylation pattern of the LumA-M1 subgroup
marks 84 samples (comprising 22 % of the 378 luminal-A
samples) as a high-risk patient group that might benefit
from more aggressive treatment.
Last, we showed that the sample partitions induced by
the gene expression and DNA methylation patterns are
related (p = 4.4e-08; see lower bar in Fig. 5c), mainly be-
cause the LumA-M3 samples that are associated with a
better outcome are enriched for LumA-R2. However,
our attempts to partition the luminal-A samples based
on both patterns together did not yield a partition that is
better than the separate partitions, in terms of survival
prediction or clustering stability. This observation was
confirmed by Cox multivariate analysis showing the in-
dependent prognostic contribution of each pattern to
outcome prediction (Table 5), suggesting that gene
expression and methylation hold complementary infor-
mation, reflecting different aspects of the biological
complexity of breast tumors.
Very recently, several novel partitions of luminal breast
tumors were proposed [19, 65, 72]. The partitions identi-
fied in this study are reinforced by partial though signifi-
cant similarity to some newly defined groups. LumA-R1
and LumA-R2 clusters are enriched for the proliferative
(p = 8.1e-04) and reactive-like (2.4-e04) classes of invasive
lobular carcinoma (ILC), respectively, as defined in [73]
(see Additional file 1, section 12). Furthermore, the
LumA-M1 cluster is enriched (p = 1.6e-07) for the Epi-
LumB group of tumors that are associated with poorer
outcome, described by Stefansson et al. [69] (named
Epi-LumB, as it was largely composed of Luminal-B
samples, see Additional file 1, section 13). Additional
research is needed in order to consolidate the differ-
ent partitions identified using different procedures
into robust and meaningful categories for prognostic
and diagnostic use in clinics.
Conclusions
This study emphasizes the large heterogeneity of luminal
breast tumors in general, and of luminal-A samples in
particular, the inner variability of which was found to be
inadequately captured by PAM50 molecular subtypes.
Analysis of the RNA-Seq data revealed a partition of the
luminal-A samples into groups associated with different
risks of 5-year recurrence. We suggest that the over-
expression of immune genes in the LumA-R2 group can
be ascribed to a higher tendency of its samples to attract
tumor-infiltrating lymphocytes, but this requires further
research into the mechanism by which the higher infil-
trates affect recurrence risk. In the DNA methylation
data, a hyper-methylation pattern enriched for develop-
mental genes defined a luminal-A subgroup that was
Netanely et al. Breast Cancer Research  (2016) 18:74 Page 15 of 16associated with poorer patient survival. In practice, the
two prognostic patterns and the lists of genomic features
characterizing each of them, can uncover the biological
aspects underlying the heterogeneity of luminal-A tumors,
improve our ability to classify these tumors into more
accurate clinical subgroups, and contribute to the devel-
opment of novel directed therapies.
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